Johns Hopkins Drug Discovery - John Hopkins University
The Johns Hopkins Drug Discovery Program continues to work with the researchers across Johns Hopkins to research and develop tomorrow’s therapeutics for a wide range of human disorders.
Johns Hopkins, Drug Discovery, Transforming academic translational research
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-2,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-4.12.1,vc_responsive
Johns Hopkins University Drug Discovery

Transforming academic
translational research

Expertise in drug
discovery research

Developing for the future

What’s New?

JHDD-cofounded PSMA Therapeutics acquired by Bayer AG

JHDD-developed glutamine antagonist receives Fast Track designation from FDA for small-cell lung cancer

JHDD coauthors a report showing glutamine antagonism overcomes tumor immune invasion [Science]

JHDD received a UG3 grant through the HEAL initiative to develop new a new treatment for neuropathic pain

Click here to read more

Partnership Awards $3 Million In Grants For Promising New Treatments In Alzheimer’s And Related Dementias

Click here to read more

Building innovative partnerships

Johns Hopkins University Drug Discovery - JHU Drug Discovery

Our high throughput screening collaboration with Eisai and partnership with Institute of Organic Chemistry and Biochemistry represent innovative ways to create a great synergy of complimentary organizations working together to develop new therapeutics.

Interested in Working With Us?

We welcome opportunities to discuss how we can work together in a drug discovery collaboration.